Fresh Funding Pushes Inflazome Into Clinic With Inflammation Inhibitors

With $46m funding fresh in its pocket, Dublin biotech Inflazome tells Scrip how it will advance its clinical candidates in multiple indications.

Money and your brain / outline of a man's head with the brain in the shape of money — • Source: Shutterstock

“This could be a new paradigm for treating multiple inflammatory diseases," Matt Cooper, CEO of Inflazome Ltd. told Scrip, when discussing the potential for the company's assets, which are about to enter the clinic in 2019. "And what's exciting is that if it works in several diseases, it may work in several more."

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Seven Up For Sanofi and Regeneron With Dupixent CSU Approval

18 Apr 2025

• By Kevin Grogan

The IL-4/IL-13 inhibitor has been approved in the US as the first targeted therapy in over a decade for chronic itching.

Disappointing Asthma Phase II Results Take Wind Out Of Sanofi’s Amlitelimab

15 Apr 2025

• By Andrew McConaghie

Sanofi’s OX40L candidate missed a Phase II primary endpoint, but the company believes it can still work in a sub-group of ‘heterogeneous inflammatory asthma’ patients.

J&J’s Icotrokinra Scores In Important Adolescent Patient Segment

11 Apr 2025

• By Alaric DeArment

The company presented positive Phase III data from a subset analysis of ICONIC-LEAD comprising patients with moderate-to-severe plaque psoriasis.

Cartesian Maps Out CAR-T Strategy With Simpler Logistics In Mind

08 Apr 2025

• By Alaric DeArment

The company announced positive Phase IIb data for Descartes-08 in myasthenia gravis, with especially strong efficacy among patients without prior biologic treatment.